A Phase 3 interventional study of Intravenous ibuprofen and Normal Saline in Tonsillectomy, sponsored by Cumberland Pharmaceuticals. Completed at 6 sites in United States. Open to participants aged 6 Years to 17 Years. Per ClinicalTrials.gov, last updated 2016-11-03.
Sponsored by Cumberland Pharmaceuticals · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The hypothesis is that a single, pre-operative dose of intravenous ibuprofen will significantly reduce post-operative fentanyl use compared to placebo.
Cumberland Pharmaceuticals is the lead sponsor of 49 studies on the registry; 1 is open to participants now.
Of its 5 completed or terminated interventional studies of FDA-regulated products, 5 (100%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: Intravenous ibuprofen
Other: Normal Saline
Participants will receive a single 10mg/kg dose of intravenous ibuprofen diluted in normal saline at the induction of anesthesia.
Participants will receive a comparable weight based volume of normal saline as a placebo comparator at the induction of anesthesia.
Number of Doses of Fentanyl Administered in the Postoperative Period Prior to Discharge.
To evaluate the primary objective of reduced fentanyl use in the post-operative period, the number of fentanyl doses (0.5 mcg/kg IV) administered in the post-operative period prior to discharge will be measured.
Time frame: 4 hours
Postoperative Pain as Measured by the Visual Analog Scale (VAS) 30 Minutes Post-procedure.
The patient's self-reported pain at 30 minutes post-procedure will be measured using a VAS scale. The VAS is a continuous scale made up of a horizontal line, 100 mm in length, anchored by 2 verbal descriptors (No Pain, Worst Possible Pain). The VAS is self-completed by the respondent. The subject is asked to place a line perpendicular to the VAS line at the point that represents their pain intensity. Using a ruler, the score is determined by measuring the distance, in mm, on the 100 mm line between the "No Pain" anchor and the subject's mark. The score would be between 0 and 100. A lower score represents less pain while a higher score represents more pain.
Time frame: 30 minutes post-procedure
Postoperative Pain as Measured by the Visual Analog Scale (VAS) 60 Minutes Post-procedure.
To evaluate the secondary objective of pain, the patient's self-reported pain at 60 minutes post-procedure will be measured using a VAS scale. The VAS is a continuous scale made up of a horizontal line, 100 mm in length, anchored by 2 verbal descriptors (No Pain, Worst Possible Pain). The VAS is self-completed by the respondent. The subject is asked to place a line perpendicular to the VAS line at the point that represents their pain intensity. Using a ruler, the score is determined by measuring the distance, in mm, on the 100 mm line between the "No Pain" anchor and the subject's mark. The score would be between 0 and 100. A lower score represents less pain while a higher score represents more pain.
Time frame: 60 minutes post-procedure
Postoperative Pain as Measured by the Visual Analog Scale (VAS) 90 Minutes Post-procedure.
o evaluate the secondary objective of pain, the patient's self-reported pain at 90 minutes post-procedure will be measured using a VAS scale. The VAS is a continuous scale made up of a horizontal line, 100 mm in length, anchored by 2 verbal descriptors (No Pain, Worst Possible Pain). The VAS is self-completed by the respondent. The subject is asked to place a line perpendicular to the VAS line at the point that represents their pain intensity. Using a ruler, the score is determined by measuring the distance, in mm, on the 100 mm line between the "No Pain" anchor and the subject's mark. The score would be between 0 and 100. A lower score represents less pain while a higher score represents more pain.
Time frame: 90 minutes post-procedure
Postoperative Pain as Measured by the Visual Analog Scale (VAS) 120 Minutes Post-procedure.
To evaluate the secondary objective of pain, the patient's self-reported pain at 120 minutes post-procedure will be measured using a VAS scale. The VAS is a continuous scale made up of a horizontal line, 100 mm in length, anchored by 2 verbal descriptors (No Pain, Worst Possible Pain). The VAS is self-completed by the respondent. The subject is asked to place a line perpendicular to the VAS line at the point that represents their pain intensity. Using a ruler, the score is determined by measuring the distance, in mm, on the 100 mm line between the "No Pain" anchor and the subject's mark. The score would be between 0 and 100. A lower score represents less pain while a higher score represents more pain.
Time frame: 120 minutes post-procedure
Time to Discharge Post Procedure.
To evaluate the secondary objective of pain, the time to participant discharge will be measured.
Time frame: Discharge
Time to Swallow Post Procedure.
Swallowing will be assessed every 15 minutes following arrival to the recovery room; the time to first swallow will be recorded.
Time frame: every 15 minutes until able to swallow
Parent Satisfaction With Regards to Pain Management Post Procedure.
To evaluate the secondary objective of pain, parental satisfaction during the post-operative period will be measured with regards to pain management. The Parental Satisfaction Survey asked the parent to base their response on their child's management from the time they arrive in the recovery room until they were discharged. Question 1 asked "How satisfied were you with your child's pain management at the time of discharge?"
Time frame: Discharge
Parent Satisfaction With Regards to Nausea Management Post Procedure.
To evaluate the secondary objective of pain, parental satisfaction during the post-operative period will be measured with regards to nausea management. The Parental Satisfaction Survey asked the parent to base their response on their child's management from the time they arrive in the recovery room until they were discharged. Question 2 asked "How satisfied were you with your child's nausea management during the study?"
Time frame: Discharge
Parental Satisfaction With Vomiting Control in the Post-Operative Period.
To evaluate the secondary objective of pain, parental satisfaction during the post-operative period will be measured with regards to vomiting control. The Parental Satisfaction Survey asked the parent to base their response on their child's management from the time they arrive in the recovery room until they were discharged. Question 3 asked "How satisfied were you with your child's vomiting management during the study?"
Time frame: Discharge
Blood Loss During Surgery
Amount of Blood Lost During Surgery in milliliters
Time frame: End of Surgery
| Milestone | Intravenous Ibuprofen | Normal Saline |
|---|---|---|
| Started | 82 | 79 |
| Completed | 82 | 79 |
| Not completed | 0 | 0 |
To evaluate the primary objective of reduced fentanyl use in the post-operative period, the number of fentanyl doses (0.5 mcg/kg IV) administered in the post-operative period prior to discharge will be measured.
| fentanyl doses | Intravenous Ibuprofen | Normal Saline |
|---|---|---|
| Number of Doses of Fentanyl Administered in the Postoperative Period Prior to Discharge. | 1.5 ± 1.32 | 1.7 ± 1.12 |
The patient's self-reported pain at 30 minutes post-procedure will be measured using a VAS scale. The VAS is a continuous scale made up of a horizontal line, 100 mm in length, anchored by 2 verbal descriptors (No Pain, Worst Possible Pain). The VAS is self-completed by the respondent. The subject is asked to place a line perpendicular to the VAS line at the point that represents their pain intensity. Using a ruler, the score is determined by measuring the distance, in mm, on the 100 mm line between the "No Pain" anchor and the subject's mark. The score would be between 0 and 100. A lower score represents less pain while a higher score represents more pain.
| millimeters | Intravenous Ibuprofen | Normal Saline |
|---|---|---|
| Postoperative Pain as Measured by the Visual Analog Scale (VAS) 30 Minutes Post-procedure. | 51 ± 30.9 | 55 ± 27.4 |
To evaluate the secondary objective of pain, the patient's self-reported pain at 60 minutes post-procedure will be measured using a VAS scale. The VAS is a continuous scale made up of a horizontal line, 100 mm in length, anchored by 2 verbal descriptors (No Pain, Worst Possible Pain). The VAS is self-completed by the respondent. The subject is asked to place a line perpendicular to the VAS line at the point that represents their pain intensity. Using a ruler, the score is determined by measuring the distance, in mm, on the 100 mm line between the "No Pain" anchor and the subject's mark. The score would be between 0 and 100. A lower score represents less pain while a higher score represents more pain.
| millimeters | Intravenous Ibuprofen | Normal Saline |
|---|---|---|
| Postoperative Pain as Measured by the Visual Analog Scale (VAS) 60 Minutes Post-procedure. | 39 ± 27.4 | 47 ± 30.8 |
o evaluate the secondary objective of pain, the patient's self-reported pain at 90 minutes post-procedure will be measured using a VAS scale. The VAS is a continuous scale made up of a horizontal line, 100 mm in length, anchored by 2 verbal descriptors (No Pain, Worst Possible Pain). The VAS is self-completed by the respondent. The subject is asked to place a line perpendicular to the VAS line at the point that represents their pain intensity. Using a ruler, the score is determined by measuring the distance, in mm, on the 100 mm line between the "No Pain" anchor and the subject's mark. The score would be between 0 and 100. A lower score represents less pain while a higher score represents more pain.
| millimeters | Intravenous Ibuprofen | Normal Saline |
|---|---|---|
| Postoperative Pain as Measured by the Visual Analog Scale (VAS) 90 Minutes Post-procedure. | 29 ± 29.3 | 35 ± 30.8 |
To evaluate the secondary objective of pain, the patient's self-reported pain at 120 minutes post-procedure will be measured using a VAS scale. The VAS is a continuous scale made up of a horizontal line, 100 mm in length, anchored by 2 verbal descriptors (No Pain, Worst Possible Pain). The VAS is self-completed by the respondent. The subject is asked to place a line perpendicular to the VAS line at the point that represents their pain intensity. Using a ruler, the score is determined by measuring the distance, in mm, on the 100 mm line between the "No Pain" anchor and the subject's mark. The score would be between 0 and 100. A lower score represents less pain while a higher score represents more pain.
| millimeters | Intravenous Ibuprofen | Normal Saline |
|---|---|---|
| Postoperative Pain as Measured by the Visual Analog Scale (VAS) 120 Minutes Post-procedure. | 22 ± 26.2 | 27 ± 29.3 |
To evaluate the secondary objective of pain, the time to participant discharge will be measured.
| hours | Intravenous Ibuprofen | Normal Saline |
|---|---|---|
| Time to Discharge Post Procedure. | 1.9 ± 0.10 | 1.9 ± 0.11 |
Swallowing will be assessed every 15 minutes following arrival to the recovery room; the time to first swallow will be recorded.
| hours | Intravenous Ibuprofen | Normal Saline |
|---|---|---|
| Time to Swallow Post Procedure. | 0.5 ± 0.04 | 0.4 ± 0.03 |
To evaluate the secondary objective of pain, parental satisfaction during the post-operative period will be measured with regards to pain management. The Parental Satisfaction Survey asked the parent to base their response on their child's management from the time they arrive in the recovery room until they were discharged. Question 1 asked "How satisfied were you with your child's pain management at the time of discharge?"
| participants | Intravenous Ibuprofen | Normal Saline |
|---|---|---|
| Strongly Agree | 58 | 58 |
| Agree | 11 | 6 |
| Neutral | 1 | 1 |
| Disagree | 2 | 0 |
| Strongly Disagree | 0 | 0 |
| Survey question not completed | 1 | 0 |
To evaluate the secondary objective of pain, parental satisfaction during the post-operative period will be measured with regards to nausea management. The Parental Satisfaction Survey asked the parent to base their response on their child's management from the time they arrive in the recovery room until they were discharged. Question 2 asked "How satisfied were you with your child's nausea management during the study?"
| participants | Intravenous Ibuprofen | Normal Saline |
|---|---|---|
| Strongly Agree | 64 | 57 |
| Agree | 7 | 5 |
| Neutral | 0 | 2 |
| Disagree | 0 | 0 |
| Strongly Disagree | 0 | 0 |
| Survey question not completed | 2 | 1 |
To evaluate the secondary objective of pain, parental satisfaction during the post-operative period will be measured with regards to vomiting control. The Parental Satisfaction Survey asked the parent to base their response on their child's management from the time they arrive in the recovery room until they were discharged. Question 3 asked "How satisfied were you with your child's vomiting management during the study?"
| participants | Intravenous Ibuprofen | Normal Saline |
|---|---|---|
| Strongly Agree | 66 | 59 |
| Agree | 3 | 4 |
| Neutral | 1 | 2 |
| Disagree | 0 | 0 |
| Strongly Disagree | 0 | 0 |
| Survey question not completed | 3 | 0 |
Amount of Blood Lost During Surgery in milliliters
| milliliters | Intravenous Ibuprofen | Normal Saline |
|---|---|---|
| Blood Loss During Surgery | 15 ± 29.6 | 16 ± 39.3 |
Non-serious events are listed at a 3% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Intravenous Ibuprofen | — | 1/82 (1.2%) | 7/82 (8.5%) |
| Normal Saline | — | 0/79 (0%) | 10/79 (12.7%) |
| Event | Intravenous Ibuprofen | Normal Saline |
|---|---|---|
| Tonsillar haemorrhageRespiratory, thoracic and mediastinal disorders | 1/82 | 0/79 |
| Event | Intravenous Ibuprofen | Normal Saline |
|---|---|---|
| AgitationNervous system disorders | 1/82 | 3/79 |
| VomitingGastrointestinal disorders | 3/82 | 2/79 |
| Infusion Site PainInjury, poisoning and procedural complications | 3/82 | 0/79 |
| RestlessnessNervous system disorders | 0/82 | 2/79 |
| Rash ErythematousSkin and subcutaneous tissue disorders | 0/82 | 2/79 |
| BronchospasmImmune system disorders | 0/82 | 2/79 |
| Age, Continuous(years) | Intravenous Ibuprofen | Normal Saline | Total |
|---|---|---|---|
| Mean | 10 ± 3.4 | 9 ± 3.0 | 9 ± 3.2 |
| Sex: Female, Male(Participants) | Intravenous Ibuprofen | Normal Saline | Total |
|---|---|---|---|
| Female | 31 | 31 | 62 |
| Male | 51 | 48 | 99 |
| Ethnicity (NIH/OMB)(Participants) | Intravenous Ibuprofen | Normal Saline | Total |
|---|---|---|---|
| Hispanic or Latino | 14 | 13 | 27 |
| Not Hispanic or Latino | 68 | 66 | 134 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | Intravenous Ibuprofen | Normal Saline | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 3 | 0 | 3 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 8 | 10 | 18 |
| White | 69 | 68 | 137 |
| More than one race | 0 | 0 | 0 |
| Unknown or Not Reported | 2 | 1 | 3 |
| Region of Enrollment(participants) | Intravenous Ibuprofen | Normal Saline | Total |
|---|---|---|---|
| United States | 82 | 79 | 161 |
The record gives a start of Jul 2011, a primary completion of Jul 2012 and a completion of Aug 2012. It does not say whether these dates are actual or estimated.
Results were first posted in Nov 2016, 4 years 4 months after primary completion. A results delay was requested in Feb 2014.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Sep 2016. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Ibuprofen